Pharmabiz1h
Santhera reports positive results from LIONHEART study with Agamree demonstrating unique mineralocorticoid receptor antagonism
Santhera reports positive results from LIONHEART study with Agamree demonstrating unique mineralocorticoid receptor antagonism: Pratteln, Switzerland Thursday, October 3, 2024, 18 ...
Pharmabiz1h
NRx Pharma announces 12-month real-time stability on first manufactured commercial scale lot of NRX-100
NRx Pharma announces 12-month real-time stability on first manufactured commercial scale lot of NRX-100: Radnor, Pennsylvania Thursday, October 3, 2024, 17:00 Hrs [IST] NRx Pharma ...
Pharmabiz2h
Dr Reddy’s inks voluntary licensing pact with Gilead to manufacture and commercialise lenacapavir in India and other countries
Dr Reddy’s inks voluntary licensing pact with Gilead to manufacture and commercialise lenacapavir in India and other countries: Our Bureau, Bengaluru Thursday, October 3, 2024, ...
Pharmabiz2h
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities ...
Pharmabiz3h
Sapience Therapeutics begins patient enrolment in phase 2 study of first-in-class ß-catenin antagonist, ST316 in colorectal cancer
Tarrytown, New York Thursday, October 3, 2024, 15:00 Hrs [IST] ...
Pharmabiz4h
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology: Venlo, the Netherlands Thursday, October 3, 2024, 14:00 Hrs [IST] Qiagen N.V., a Netherlands-base ...
Pharmabiz3h
CDSCO becomes affiliated member of IMDRF
The Central Drugs Standard Control Organization (CDSCO) has received approval from International Medical Device Regulators Forum (IMDRF) as an affiliate member of the Forum. The ministry of health and ...
Pharmabiz6h
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility: Our Bureau, Bengaluru Thursday, October 3, 2024, 12:30 Hrs [IST] Biocon B ...
Pharmabiz7h
Eppendorf introduces CO2 incubator shaker, CellXpert CS220 on the market with integrated 180°C sterilization routine
Eppendorf introduces CO2 incubator shaker, CellXpert CS220 on the market with integrated 180°C sterilization routine: Hamburg, Germany Thursday, October 3, 2024, 11:00 Hrs [IST] ...
Pharmabiz7h
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...
Pharmabiz6h
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 12:10 Hrs [IST] The Joint United Nations Progra ...
Pharmabiz6h
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403: Cambridge, Massachusetts Thursday, October 3, 2024, 12:00 Hrs [IST] Moderna, Inc, a global l ...